Cover Image
市場調查報告書

奈米粒子藥物遞輸市場及臨床實驗開發平台(管線)預測

Nanoparticle Drug Delivery Market & Clinical Pipeline Insight

出版商 KuicK Research 商品編碼 304889
出版日期 內容資訊 英文 475 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
奈米粒子藥物遞輸市場及臨床實驗開發平台(管線)預測 Nanoparticle Drug Delivery Market & Clinical Pipeline Insight
出版日期: 2014年06月01日 內容資訊: 英文 475 Pages
簡介

使用1∼100 nm大小的奈米粒子的藥物遞輸系統由於擁有高未來性而進行活躍開發。奈米粒子擁有將恰當數量的藥物分子送到各種領域的能力,還有和其他方法比較,能持續更長時間提供藥物分子。現在作為治療用的奈米載體候補之微脂體以及白蛋白奈米粒子正急速受到注目,預計不久後會在市場生根。

本報告提供奈米粒子藥物遞輸市場、臨床實驗開發平台上等待上市的新藥物的詳查、奈米粒子藥物遞輸市場現狀、推動市場成長要素和市場課題等市場動態、今後市場預測詳細分析。還有臨床實驗開發平台上處於開發階段的奈米粒子藥物、已經核准、市售的藥物、開發中止的藥物各種相關研究、市場未來性的資料。再加上市場競爭環境與主要企業詳細分析。

第1章 藥物遞輸的奈米粒子技術序論

第2章 使用奈米粒子的藥物遞輸機制

  • 蛋白質為基礎的給藥系統
  • 天然聚合物及衍生物
  • 聚合物電信業者
  • 樹狀聚合物
  • 富勒烯
  • 奈米碳管

第3章 針對藥物遞輸的奈米技術的應用

第4章 奈米粒子藥物遞輸市場概要

  • 市場概要
  • 臨床實驗開發平台預測

第5章 奈米粒子藥物遞輸市場動態

  • 推動市場成長要素
  • 課題
  • 未來發展預測

第6章 各階段、各國,及各對象疾病之奈米粒子藥物遞輸的臨床實驗平台分析

  • 研究階段
  • 臨床前實驗階段
  • 臨床試驗階段I
  • 臨床試驗階段I/II
  • 臨床試驗階段II
  • 臨床試驗階段II/III
  • 臨床試驗階段III

第7章 市售的奈米粒子藥物

第8章 開發暫時停止或全面停止的奈米粒子藥物

  • 開發無通知
  • 開發停止
  • 開發暫時停止

第9章 市場競爭情形

  • Abraxis BioScience
  • Access Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Arrowhead Research
  • BIND Biosciences
  • iCeutica
  • NanoCarrier
  • 日本化藥
  • Nanobiotix
  • Samyang
目錄

Drug delivery technologies currently occupy a significant position in the pharmaceutical industry. It has become so important that the mode of delivery of drugs has come to define the efficiency and marketability of those drugs. The pharmaceutical industry is witnessing a shift in the focus of the stakeholders towards newer systems of drug delivery in order to achieve efficient and safe transportation of novel products and formulations. There have been many products which have been derived from new delivery systems and are currently attracting the attention of different companies. It has been recognized that the introduction of a new drug delivery system would bring along a potential chance for an existing drug candidate molecule.

The field of nanotechnology is considered to be an exciting area which offers the potential for developing drug delivery systems using nanoparticles, with dimension range of 1-100 nm. These nanoparticles tend to have the ability to deliver an adequate range of molecules to different areas of the body. Additionally, these nanoparticles also posses the capability to deliver the molecules for a comparatively longer duration of time as compared to other routes. The major objectives of a drug delivery system based on nanoparticles, are size of particles, surface properties and discharge of drugs or the active ingredients in order to attain the maximum level of efficiency.

The combination of nanotechnology along with medicine has resulted in potential concepts and ideas for the pharma industry which is set to introduce momentous innovations in the fight against different diseases. The two concepts of therapeutic nanocarriers - liposomes and albumin nanoparticles are gaining prominence rapidly and would soon become well-established in the market across the globe. The need of the hour currently is to obtain a deeper understanding of the biodistribution of nanoparticles, which is influenced mainly by their ability to negotiate biological barriers.

Additionally, a significant growth of this field would mostly depend on the strong establishment of a toxicology database which would support the safety determinations and risk assessments. This database could possibly include toxicity as a function of material, size, shape, cell type or animal, duration of exposure and the methods which are used to assay toxicity. Also, there needs to be a mechanism wherein the scaling up of production levels of drug particles is enabled. Finally, this database should also consider protocols relating to storage and handling. The use of such a compact database would help the pharma industry to translate biomedical nanotechnology from the laboratory to the general public at ease.

“Nanoparticle Drug Delivery Market & Clinical Pipeline Insight” Report Highlights:

  • Nanoparticle Drug Delivery Market Overview
  • Nanoparticle Drug Delivery Mechanism
  • Clinical Pipeline by Phase & Target Indications
  • Drug Profiles in Report: 190
  • Majority of Nanoparticle Drug in Preclinical Phase: 70
  • Marketed Nanoparticle Drugs: 12
  • Suspended & Discontinued Drug Profiles

Table of Contents

1. Introduction to Nanoparticle Technology for Drug Delivery

2. Nanoparticle Drug Delivery Mechanism

  • 2.1 Protein Based Delivery Systems
  • 2.2 Natural Polymers & Derivates
  • 2.3 Polymeric Carriers
  • 2.4 Dendrimers
  • 2.5 Fullerene
  • 2.6 Carbon Nanotubes

3. Application of Nanotechnology for Drug Delivery

4. Nanoparticle Drug Delivery Market Overview

  • 4.1 Market Overview
  • 4.2 Clinical Insight

5. Nanoparticle Drug Delivery Market Dynamics

  • 5.1 Drivers
  • 5.2 Challenges
  • 5.3 Future Outlook

6. Nanoparticle Drug Delivery Clinical Pipeline by Phase, Country & Indication

  • 6.1 Research
  • 6.2 Preclinical
  • 6.3 Phase I
  • 6.4 Phase I/II
  • 6.5 Phase II
  • 6.6 Phase II/III
  • 6.7 Phase III

7. Marketed Nanoparticle Drug

8. Suspended & Discontinued Nanoparticle Drug Profiles

  • 8.1 No Development Reported
  • 8.2 Discontinued
  • 8.3 Suspended

9. Competitive Landscape

  • 9.1 Abraxis BioScience
  • 9.2 Access Pharmaceuticals
  • 9.3 Alnylam Pharmaceuticals
  • 9.4 Arrowhead Research
  • 9.5 BIND Biosciences
  • 9.6 iCeutica
  • 9.7 NanoCarrier
  • 9.8 Nippon Kayaku
  • 9.9 Nanobiotix
  • 9.10 Samyang

List of Figures

  • Figure 1-1: Nanoparticle Technology for Drug Delivery
  • Figure 1-2: Nanoparticle Class
  • Figure 2-1: Nanoparticle Drug Delivery System
  • Figure 4-1: Nanoparticle Drug Delivery Market (US$ Billion), 2013-2020
  • Figure 4-2: Nanoparticle Drugs in Clinical Pipeline by Phase (%)
  • Figure 4-3: Number Nanoparticle Drugs in Clinical Pipeline by Phase (%)
  • Figure 4-4: No Development in Nanoparticle Drugs in Clinical Pipeline by Phase (%)
  • Figure 4-5: Number of No Development in Nanoparticle Drugs in Clinical Pipeline by Phase
  • Figure 4-6: Discontinued Nanoparticle Drugs in Clinical Pipeline by Phase (%)
  • Figure 4-7: Number of Discontinued Nanoparticle Drugs in Clinical Pipeline by Phase
  • Figure 4-8: Suspended Nanoparticle Drugs in Clinical Pipeline by Phase (%)
  • Figure 4-9: Number of Suspended Nanoparticle Drugs in Clinical Pipeline by Phase
  • Figure 9-1: Arrowhead Research Corporation Clinical Pipeline
  • Figure 9-2: NanoCarrier Clinical Pipeline
Back to Top